Quest Diagnostics Incorporated (DGX)
NYSE: DGXHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:01 PM ET · Delayed 15 min
DGX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $28.42B
- P/E (TTM)
- 25.73
- Forward P/E
- 21.55
- EPS (TTM)
- $10.04
- Dividend yield
- 1.31% ($3.38)
- Ex-dividend date
- Oct 6, 2026
- 52-week range
- 171.18 – 263.19
- Day range
- 257.56 – 262.96
- Volume / Avg
- 1.37M / 1.03M
- Beta
- —
- Shares outstanding
- 110.02M
52-week range
DGX stock today
Quest Diagnostics (DGX) closed at $258.28 on Nov 20, down 0.31% (-$0.81), versus the S&P 500's 3.70% decline. Shares are 1.9% below their 52-week high of $263.19, set on Nov 16, 2026 and 50.9% above the 52-week low of $171.18, near the top of the past year's range. DGX is up 48.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 35.0%.
At 25.7x trailing earnings, Quest Diagnostics trades below the peer-group median of 30.1x. Its forward P/E of 21.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Quest Diagnostics pays an annual dividend of $3.38 per share, a 1.31% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Quest Diagnostics
Company profileQuest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. James E. Davis
- Headquarters
- Secaucus, NJ
- Employees
- 60,000
- Website
- questdiagnostics.com
Financial highlights
Full financialsIn fiscal 2025, Quest Diagnostics generated $11.04 billion in revenue, up 11.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $992.0 million (+13.9% year over year), for a net margin of 9.0% versus a median of 9.6% in the prior 5 years. Gross margin was 33.2% (up from 32.9%) and operating margin 14.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Growth | +11.78% | +6.70% | -6.38% | -8.39% | +14.32% |
| Net income | $992.00M | $871.00M | $854.00M | $946.00M | $2.00B |
| EPS (diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
Analyst forecast
ForecastConsensus (17 analysts)
buy
Avg. price target
$257.27-0.39%
- Strong buy 2
- Buy 7
- Hold 8
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 22, 2026
- EPS actual vs est.
- $3.00 vs $2.85
- Surprise
- +5.26%
Dividends
Dividend history- Annual dividend
- $3.38
- Dividend yield
- 1.31%
- Last payment
- $0.86
- Ex-dividend date
- Oct 6, 2026
DGX news
All DGX news- Quest Diagnostics Stock Gains 49.3% YTD: What's Behind the Rally?NasdaqDGX, IDXX, PODD, BLCO
- Quest Diagnostics Incorporated (DGX) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Here's Why Quest Diagnostics (DGX) is a Strong Value StockNasdaq
- Quest Diagnostics Declares Quarterly Cash DividendPR Newswire
- Quest Diagnostics Reaches Analyst Target PriceNasdaqDGX, BIO.B
- Quest Diagnostics to Speak at the 9th Annual Evercore Healthcare ConferencePR NewswireDGX, EVR
- Quest Diagnostics to Speak at the Jefferies Global Healthcare Conference in LondonPR Newswire
- IBD Stock Of The Day Quest Diagnostics Is Bucking The Medtech MalaiseInvestor's Business Daily
Quest Diagnostics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ILMNIllumina Inc. | 192.82 | -3.90% | $29.15B | vs DGX |
| LHLabcorp Holdings Inc. | 367.13 | -0.47% | $29.81B | vs DGX |
| CNCCentene Corporation | 63.78 | -2.74% | $31.58B | vs DGX |
| GHGuardant Health Inc. | 145.83 | +0.16% | $19.73B | vs DGX |
| NTRANatera Inc. | 273.40 | -5.70% | $39.64B | vs DGX |
| MOHMolina Healthcare Inc | 198.39 | -2.43% | $10.36B | vs DGX |
| HUMHumana Inc. | 390.00 | +2.63% | $46.84B | vs DGX |
| HSICHenry Schein Inc. | 83.52 | -1.51% | $9.23B | vs DGX |
Indexes, lists and sector
Quest Diagnostics stock FAQ
What is Quest Diagnostics's stock price today?
DGX last traded at $258.28 as of Nov 20, 4:01 PM EST, down 0.31% on the day. Prices are delayed at least 15 minutes.
Does Quest Diagnostics pay a dividend?
Yes. Quest Diagnostics pays $3.38 per share annually, a 1.31% yield. The most recent dividend of $0.86 had an ex-dividend date of Oct 6, 2026.
What is DGX's P/E ratio?
DGX trades at a trailing P/E ratio of 25.73 and a forward P/E of 21.55, compared with a median of 30.1 for its closest peers.
Is Quest Diagnostics in the S&P 500?
Yes. Quest Diagnostics (DGX) is a constituent of the S&P 500 index.
Who is Quest Diagnostics's CEO?
Mr. James E. Davis is the chief executive officer of Quest Diagnostics Incorporated, which has about 60,000 employees.
Has DGX ever split its stock?
Yes. The most recent DGX stock split was a 2-for-1 split on Jun 21, 2005, one of 2 splits on record.
What is the DGX 52-week high?
The 52-week high for DGX is $263.19 and the 52-week low is $171.18. The stock is currently 1.9% below its high.